|[April 23, 2014]
Research and Markets: Global Hepatitis C Therapeutics in Major Developed Markets 2013-2019
DUBLIN --(Business Wire)--
Research and Markets (http://www.researchandmarkets.com/research/q3nxmh/hepatitis_c)
has announced the addition of the "Global
Hepatitis C Therapeutics in Major Developed Markets 2013-2019"
report to their offering.
The global market has the potential to grow to a value of $18.6 billion
by 2019, more than tripling the 2012 market value of $5.8 billion
Hepatitis C Therapeutics in Major Developed Markets to 2019 -
Outstanding Recent Approvals and Late-Stage Pipeline to Transform
Clinical and Commercial Landscape. The current Hepatitis C treatment
landscape consists of a combination of pegylated interferon, ribavirin
and, in patients infected with genotype 1 hepatitis C, one of two
direct-acting antiviral agents (DAAs). Products with these mechanisms of
action have performed strongly in the commercial setting, with the
market leader Incivek (a DAA) having reached blockbuster sales.
However, these products are very poorly tolerated and only moderately
efficacious. The approval of the DAA Sovaldi in December 2013 changed
this, with a complete viral clearance being achieved in close to 100% of
patients and a much improved adverse event profile compared to previous
standards of therapy. In patients with genotype 2 and 3 hepatitis C,
Sovaldi does not need to be administered with pegylated interferon.
A number of products in the late-stage pipeline, which promise to be
even more efficacious and safe are anticipated to enter the market over
the forecast period, includingseveral interferon-free therapies for
genotype 1-infected patients. As a result of this, as well as an overall
increase in the treated population, the authors believe the global
market has the potential to grow to a value of $18.6 billion by 2019,
more than tripling the 2012 market value of $5.8 billion.
A brief introduction to hepatitis C, including the disease's
pathogenesis, risk factors and diagnosis, and detailed analyses of
disease epidemiology and treatment algorithms.
In-depth analysis of the major antiviral drugs used in the treatment
of hepatitis C, including analyses of their safety, efficacy,
treatment patterns and strengths/weaknesses. Includes a heat map that
compares marketed drugs in terms of safety and efficacy.
A comprehensive review of the pipeline for hepatitis C therapies,
including individual analysis of a number of late-stage pipeline drugs
that are likely to enter the market during the forecast period. The
pipeline is analyzed by phase distribution, molecule type and
In-depth clinical trial enrolment, trial duration and program failure
rate analyses for each molecule type and mechanism of action.
Additionally, clinical trial endpoints and certain selection criteria
are analyzed in great depth. This section also includes an additional
heat map regarding pipeline products, and a direct cross-analysis
against currently marketed products.
Multi-scenario forecast data of the market to 2019, which takes into
account the effects of the introduction of new drugs, the expiry of
key patents on current drugs and the changes in disease epidemiology
across the key developed markets: US, Canada, Japan, Germany, UK,
France, Italy and Spain.
Discussion of the drivers and barriers for market growth.
Analysis of licensing and co-development deals occurring in the
hepatitis C market.
Key Topics Covered:
1 Tables & Figures
Signs and Symptoms
Etiology and Risk Factors
Prognosis (News - Alert)
3 Marketed Products
Pegasys (Peginterferon alfa 2a) and PegIntron (Peginterferon alfa 2b)
- Hoffmann La Roche and Merck & Co
Incivek (telaprevir) - Vertex (News - Alert) Pharmaceuticals and Janssen-Cilag
Victrelis (boceprevir) - Merck & Co
Olysio (simeprevir) - Johnson and Johnson
Sovaldi (sofosbuvir) - Gilead Sciences
Heat Map for Marketed Products
4 Developmental Pipeline
Mechanisms of Action
Promising Pipeline Drugs
Heat Map and Competitor Matrix for Pipeline Products
5 Market Forecast to 2019
6 Drivers and Barriers
7 Licensing and Co-development deals
For more information visit http://www.researchandmarkets.com/research/q3nxmh/hepatitis_c
[ Back To TMCnet.com's Homepage ]